SCHEMBL4618809

SCHEMBL4618809

CC(C)(C)OC(=O)NCc1ccc(C(=N)NO)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.52
HDAC6 Q9UBN7 5/20 0.49
HDAC10 Q969S8 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HDAC1 Q13547 4/20 0.48
GAA P10253 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HPN P05981 1/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
KDM4A O75164 1/20 0.44
FPR3 P25089 1/20 0.43
FPR2 P25090 1/20 0.43
GLS O94925 1/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25054251 0.87 NAMPT (0.51) NAMPTHDAC6HDAC10L3MBTL1HDAC1
SCHEMBL23201202 0.86 NAMPT (0.50) NAMPTHDAC6HDAC10L3MBTL1HDAC1
SCHEMBL3180689 0.84 L3MBTL1 (0.61) NAMPTHDAC6HDAC10L3MBTL1HDAC1
SCHEMBL8494151 0.84 HPN (0.57) NAMPTL3MBTL1HDAC1GAAHPN
SCHEMBL25054042 0.83 NAMPT (0.47) NAMPTL3MBTL1HDAC1GAAHPN
SCHEMBL10165179 0.82 NAMPT (0.56) NAMPTHDAC6HDAC10L3MBTL1HDAC1
SCHEMBL133327 0.82 KMT2A (0.60) NAMPTL3MBTL1HDAC1GAACA1
SCHEMBL8127981 0.82 EPHX2 (0.59) NAMPTHDAC6HDAC10L3MBTL1HDAC1
SCHEMBL25054032 0.81 MASP2 (0.49) NAMPTL3MBTL1HDAC1GAAHPN
SCHEMBL25054043 0.81 MASP2 (0.48) NAMPTL3MBTL1HDAC1GAAHPN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands NOVARTIS AG (CH) 2008-12-11 US disclosed
EP-1893591-A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS Novartis AG (CH) 2008-03-05 EP disclosed
WO-2006131336-A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS NOVARTIS AG (CH) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands SOX18, SIGMAR1, SUCNR1 NAMPT 4275/4885HDAC6 2516/4885HDAC10 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.